© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Schrödinger, Inc. (SDGR) stock declined over -1.75%, trading at $19.50 on NASDAQ, down from the previous close of $19.85. The stock opened at $19.57, fluctuating between $19.46 and $20.13 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 19, 2026 | 18.12 | 19.92 | 18.12 | 19.85 | 1.89M |
| Aug 18, 2026 | 17.31 | 17.72 | 17.17 | 17.67 | 836.99K |
| Aug 17, 2026 | 17.36 | 17.60 | 17.16 | 17.40 | 650.25K |
| Aug 14, 2026 | 18.46 | 18.50 | 17.58 | 17.59 | 947.41K |
| Aug 13, 2026 | 18.56 | 18.84 | 18.32 | 18.46 | 920.15K |
| Aug 12, 2026 | 18.60 | 18.73 | 18.21 | 18.63 | 1.48M |
| Aug 11, 2026 | 18.77 | 19.24 | 18.60 | 18.65 | 1.43M |
| Aug 10, 2026 | 18.02 | 18.94 | 17.95 | 18.77 | 1.2M |
| Aug 07, 2026 | 18.08 | 18.85 | 17.49 | 18.16 | 1.37M |
| Aug 06, 2026 | 17.26 | 18.38 | 17.02 | 17.81 | 2.74M |
| Aug 05, 2026 | 15.75 | 16.49 | 15.52 | 16.40 | 1.71M |
| Aug 04, 2026 | 15.30 | 15.75 | 15.20 | 15.65 | 969.9K |
| Aug 03, 2026 | 15.14 | 15.51 | 14.91 | 15.28 | 982.15K |
| Jul 31, 2026 | 15.34 | 15.52 | 14.80 | 15.14 | 1.22M |
| Jul 30, 2026 | 15.02 | 15.47 | 14.72 | 15.35 | 879.21K |
| Jul 29, 2026 | 15.15 | 15.45 | 14.94 | 15.12 | 659.59K |
| Jul 28, 2026 | 15.26 | 15.57 | 15.07 | 15.29 | 530.39K |
| Jul 27, 2026 | 15.20 | 15.50 | 15.00 | 15.28 | 642.9K |
| Jul 24, 2026 | 15.32 | 15.35 | 14.61 | 14.97 | 980.49K |
| Jul 23, 2026 | 14.85 | 15.40 | 14.85 | 15.13 | 711.59K |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
| Employees | 850 |
| Beta | 1.66 |
| Sales or Revenue | $216.67M |
| 5Y Sales Change% | 1.195% |
| Fiscal Year Ends | December |
| Sector | Technology |
| Industry | Software - Application |